ULTRAGENYX PHARMACEUTICAL INC. Effective Income Tax Rate Reconciliation, Tax Contingency, Foreign, Amount
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Effective Income Tax Rate Reconciliation, Tax Contingency, Foreign, Amount of $5.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-18.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxContingenciesForeign · last filed 2026-02-18
- ULTRAGENYX PHARMACEUTICAL INC. effective income tax rate reconciliation, tax contingency, foreign, amount for fiscal 2025 was $5.00M.
| Period end | Effective Income Tax Rate Reconciliation, Tax Contingency, Foreign, Amount 12 month |
|---|---|
| 2025-12-31 | $5.00M 10-K · filed 2026-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |